b-Arrestins in the Central Nervous System - Progress in Molecular Biology and Translational Science - page 285

132. Przewlocka B, Sieja A, Starowicz K, Maj M, Bilecki W, Przewlocki R. Knockdown of
spinal opioid receptors by antisense targeting beta-arrestin reduces morphine tolerance
and allodynia in rat. Neurosci Lett . 2002;325(2):107 - 110.
133. Schmid CL, Bohn LM. Physiological and pharmacological implications of beta-arrestin
regulation. Pharmacol Ther . 2009;121(3):285 - 293.
134. Zhang J, Ferguson SS, Barak LS, et al. Role for G protein-coupled receptor kinase in
agonist-specific regulation of mu-opioid receptor responsiveness. Proc Natl Acad Sci
USA . 1998;95(12):7157 - 7162.
135. Whistler JL, von Zastrow M. Morphine-activated opioid receptors elude desensitiza-
tion by beta-arrestin. Proc Natl Acad Sci USA . 1998;95(17):9914 - 9919.
136. Bohn LM, Gainetdinov RR, Caron MG. G protein-coupled receptor kinase/beta-
arrestin systems and drugs of abuse: psychostimulant and opiate studies in knockout
mice. Neuromolecular Med . 2004;5(1):41 - 50.
137. Bohn LM, Dykstra LA, Lefkowitz RJ, Caron MG, Barak LS, et al. Relative opioid effi-
cacy is determined by the complements of the G protein-coupled receptor desensiti-
zation machinery. Mol Pharmacol . 2004;66(1):106 - 112.
138. Hauger RL, Risbrough V, Brauns O, Dautzenberg FM. Corticotropin releasing factor
(CRF) receptor signaling in the central nervous system: new molecular targets. CNS
Neurol Disord Drug Targets . 2006;5(4):453- 479.
139. Hauger RL, Olivares-Reyes JA, Dautzenberg FM, Lohr JB, Braun S, Oakley RH.
Molecular and cell signaling targets for PTSD pathophysiology and pharmacotherapy.
Neuropharmacology . 2012;62(2):705 - 714.
140. Bale TL, Vale WW. CRF and CRF receptors: role in stress responsivity and other
behaviors. Annu Rev Pharmacol Toxicol . 2004;44:525 - 557.
141. Holsboer F, Ising M. Central CRH system in depression and anxiety—evidence from
clinical studies with CRH1 receptor antagonists. Eur J Pharmacol . 2008;583

(2 - 3):350- 357.
142. Grigoriadis DE. The corticotropin-releasing factor receptor: a novel target for the treat-
ment of depression and anxiety-related disorders. Expert Opin Ther Targets . 2005;9
(4):651 - 684.
143. Cryan JF, Holmes A. The ascent of mouse: advances in modelling human depression
and anxiety. Nat Rev Drug Discov . 2005;4(9):775 - 790.
144. Tezval H, Jahn O, Todorovic C, Sasse A, Eckart K, Spiess J. Cortagine, a specific ago-
nist of corticotropin-releasing factor receptor subtype 1, is anxiogenic and
antidepressive in the mouse model. Proc Natl Acad Sci USA . 2004;101(25):9468 - 9473.
145. Heinrichs SC, Koob GF. Corticotropin-releasing factor in brain: a role in activation,
arousal, and affect regulation. J Pharmacol Exp Ther . 2004;311(2):427 - 440.
146. Coste SC, Murray SE, Stenzel-Poore MP. Animal models of CRH excess and CRH
receptor deficiency display altered adaptations to stress. Peptides . 2001;22(5):733 - 741.
147. Muller MB, Holsboer F. Mice with mutations in the HPA-system as models for symp-
toms of depression. Biol Psychiatry . 2006;59(12):1104 - 1115.
148. Hauger RL, Risbrough V, Oakley RH, Olivares-Reyes JA, Dautzenberg FM. Role of
CRF receptor signaling in stress vulnerability, anxiety, and depression. Ann N Y Acad
Sci . 2009;1179:120 - 143.
149. Teli T, Markovic D, Levine MA, Hillhouse EW, Grammatopoulos DK. Regulation of
corticotropin-releasing hormone receptor type 1alpha signaling: structural determi-
nants for G protein-coupled receptor kinase-mediated phosphorylation and agonist-
mediated desensitization. Mol Endocrinol . 2005;19(2):474 - 490.
150. Dautzenberg FM, Braun S, Hauger RL. GRK3 mediates desensitization of CRF1
receptors: a potential mechanism regulating stress adaptation. Am J Physiol Regul Integr
Comp Physiol . 2001;280(4):R935 - R946.